Adeline P.
- Country
- France
- Department
- Radiothérapie
Research Overview
- De-escalation of endocrine therapy in postmenopausal women with low-risk HR+ HER2- low Luminal A early breast cancer: a single-arm study of omission versus combination therapy
- Phase II Randomized Trial of Atezolizumab with Chemoradiotherapy in Locally Advanced Cervical Cancer
- Phase II Multicenter Randomized Open-Label Study of Relatlimab and Nivolumab Versus Nivolumab in Locally Advanced Cervical Cancer
Data & Insights
Has run more than one trial at 23 of 63 partner sites.
Specializations
Gynecologic Oncology
This investigator specializes in treating locally advanced cervical cancer, with particular emphasis on innovative therapeutic approaches. Their research explores the integration of immunotherapy treatments in cervical cancer management.
- Advanced Stage Cervical Carcinoma
- Immune Checkpoint Inhibition
- Combined Modality Treatment
Their expertise extends to managing both squamous and adenosquamous carcinomas of the cervix.
Immunotherapy Research
The investigator focuses on developing novel immunotherapeutic approaches for gynecologic cancers, particularly exploring the role of PD-L1 inhibition and combination immunotherapy strategies.
- Checkpoint Inhibitor Combinations
- Immunotherapy Integration
- Treatment Response Assessment
Their work includes evaluation of innovative drug combinations in the context of standard treatment protocols.
Therapeutic Innovation
The investigator's research encompasses multimodal treatment approaches, combining standard therapies with novel agents for improved patient outcomes.
- Chemoradiotherapy Enhancement
- Treatment Sequencing
- Disease Progression Monitoring
Their work involves evaluating treatment efficacy using standardized response criteria in clinical trials.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.